Eric H Westin Selected Research

litronesib

2/2017	Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
11/2015	A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric H Westin Research Topics

Disease

4	Neoplasms (Cancer) 01/2022 - 11/2015
1	Hyperglycemia 09/2017
1	Mucositis 02/2017
1	Neutropenia 02/2017
1	Stomatitis 02/2017

Drug/Important Bio-Agent (IBA)

2	litronesibIBA 02/2017 - 11/2015
1	Immunoconjugates (Immunoconjugate)IBA 01/2022
1	AntibodiesIBA 01/2022
1	Protein Isoforms (Isoforms)IBA 09/2017
1	serabelisibIBA 09/2017
1	Pharmaceutical PreparationsIBA 09/2017
1	pegfilgrastim (Neulasta)FDA Link 02/2017
1	Biomarkers (Surrogate Marker)IBA 11/2015

Therapy/Procedure

1	Therapeutics 09/2017
1	Drug Therapy (Chemotherapy) 11/2015